Medical Oncology

APT trial, 10-летние результаты
Адъювантный трастузумаб+ паклитаксел, при HER2+ раке молочной железы T1-2 (до 3см) N0.
Single-arm, phase 2 study.

10-year invasive disease-free survival - 91·3% (95% CI 88·3–94·4)
10-year recurrence-free interval - 96·3% (95% CI 94·3–98·3)
10-year overall survival - 94·3% (95% CI 91·8–96·8)
10-year breast cancer-specific survival - 98·8% (95% CI 97·6–100).

На слайде:
10-year invasive disease-free survival, overall (A) and by hormone receptor status (B), sTIL expression (C), and PAM50 subtype (D)

https://www.sciencedirect.com/science/article/pii/S1470204523000517?dgcid=author

www.tgoop.com/medonco/875

1.8K viewsAliaksei, Feb 28, 2023 at 19:53

APT trial, 10-летние результаты
Адъювантный трастузумаб+ паклитаксел, при HER2+ раке молочной железы T1-2 (до 3см) N0.
Single-arm, phase 2 study.

10-year invasive disease-free survival - 91·3% (95% CI 88·3–94·4)
10-year recurrence-free interval - 96·3% (95% CI 94·3–98·3)
10-year overall survival - 94·3% (95% CI 91·8–96·8)
10-year breast cancer-specific survival - 98·8% (95% CI 97·6–100).

На слайде:
10-year invasive disease-free survival, overall (A) and by hormone receptor status (B), sTIL expression (C), and PAM50 subtype (D)

https://www.sciencedirect.com/science/article/pii/S1470204523000517?dgcid=author

BY Medical Oncology